American Diabetes Association
Browse
UpdatedSupplementaryMaterial.pdf (3.54 MB)

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post-Hoc Analysis

Download (3.54 MB)
figure
posted on 2023-06-02, 19:10 authored by Hiddo J L Heerspink, Naveed Sattar, Imre Pavo, Axel Haupt, Kevin L Duffin, Zhengyu Yang, Russell J Wiese, Jonathan M Wilson, Andrea Hemmingway, David Z I Cherney, Katherine R Tuttle

  

Objective

Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike eGFR-creatinine, eGFR-cystatin C is unaffected by muscle mass changes. We assessed effects of tirzepatide on eGFR-creatinine and -cystatin C.

Research Design and Methods

Our primary outcome was eGFR change from baseline at 52 weeks with pooled tirzepatide (5, 10, 15 mg) and titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk (SURPASS-4).

Results

LSM (SE) eGFR-creatinine (mL/min/1.73m2) change from baseline with tirzepatide and insulin glargine was -2.5 (0.38) and -3.9 (0.38) (between-group difference 1.4 [95% CI, 0.3 to 2.4]), and was -3.5 (0.37) and -5.3 (0.37) (between-group difference 1.8 [0.8 to 2.8]) for eGFR-cystatin C. Baseline, 1-year, and 1-year change from baseline values significantly correlated between eGFR-cystatin C and -creatinine. eGFR-measure changes did not correlate with body weight changes.

Conclusions

Tirzepatide slows the eGFR decline rate, supporting a kidney-protective effect. 

Funding

Eli Lilly and Company

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC